Format

Send to

Choose Destination
Nat Rev Genet. 2018 Feb;19(2):93-109. doi: 10.1038/nrg.2017.96. Epub 2017 Dec 27.

Cancer transcriptome profiling at the juncture of clinical translation.

Author information

1
Michigan Center for Translational Pathology, University of Michigan.
2
Department of Pathology, University of Michigan.
3
Comprehensive Cancer Center, University of Michigan.
4
Department of Urology, University of Michigan.
5
Howard Hughes Medical Institute, University of Michigan, Ann Arbor, Michigan 48109, USA.

Abstract

Methodological breakthroughs over the past four decades have repeatedly revolutionized transcriptome profiling. Using RNA sequencing (RNA-seq), it has now become possible to sequence and quantify the transcriptional outputs of individual cells or thousands of samples. These transcriptomes provide a link between cellular phenotypes and their molecular underpinnings, such as mutations. In the context of cancer, this link represents an opportunity to dissect the complexity and heterogeneity of tumours and to discover new biomarkers or therapeutic strategies. Here, we review the rationale, methodology and translational impact of transcriptome profiling in cancer.

PMID:
29279605
DOI:
10.1038/nrg.2017.96
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center